Literature DB >> 20400233

The best immunohistochemical panel for differentiating hepatocellular carcinoma from metastatic adenocarcinoma.

Ayca Karabork1, Gulsah Kaygusuz, Cemil Ekinci.   

Abstract

It can be difficult to differentiate hepatocellular carcinoma (HCC) from metastatic adenocarcinoma (MA). An appropriate immunohistochemical panel is required for the differential diagnosis. This study aimed at finding the best panel, including hepatocyte-specific antigen (Hepatocyte), pCEA, CD10, Villin, CD34, TTF-1, MOC-31, CK7, and CK20 antibodies. Sixty-eight cases of HCC and 107 cases of MA were investigated. Hepatocyte positivity was seen in 95.6% of HCCs and in 1.9% of MAs. pCEA was expressed in 47.8% of HCCs and in 86.8% of MAs. CD10 stained 73.13% of HCCs and 36.9% of MAs. Villin was positive in 23.5% of HCCs and in 81.0% of MAs. Canalicular staining with pCEA, CD10, and Villin was seen only in HCCs. Sinusoidal CD34 staining was seen only in 42.6% of HCCs. A small subset of HCCs demonstrated cytoplasmic TTF-1 and MOC-31. CK7 was expressed in 29.4% of HCCs and in 29.9% of MAs, whereas CK20 stained 14.7% of HCCs and 62.6% of MAs. In conclusion, Hepatocyte should be combined with pCEA, MOC-31, CD10, and CD34. Canalicular staining with pCEA, CD10, and Villin is specific for HCC. CK7 and CK20 expression may be seen in some HCCs. We suggest that the best panel for discriminating HCC from MA should contain Hepatocyte, MOC-31, pCEA, CD10, and CD34.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20400233     DOI: 10.1016/j.prp.2010.03.004

Source DB:  PubMed          Journal:  Pathol Res Pract        ISSN: 0344-0338            Impact factor:   3.250


  8 in total

1.  The Applicability of a Human Immunohistochemical Panel to Mouse Models of Hepatocellular Neoplasia.

Authors:  Kenneth J Salleng; Frank L Revetta; Natasha G Deane; M Kay Washington
Journal:  Comp Med       Date:  2015-10       Impact factor: 0.982

2.  The Diagnostic Value of Arginase-1, FTCD, and MOC-31 Expression in Early Detection of Hepatocellular Carcinoma (HCC) and in Differentiation Between HCC and Metastatic Adenocarcinoma to the Liver.

Authors:  Osama H Labib; Ola A Harb; Osama H Khalil; Taha A Baiomy; Loay M Gertallah; Rham Z Ahmed
Journal:  J Gastrointest Cancer       Date:  2020-03

Review 3.  Histopathology of hepatocellular carcinoma.

Authors:  Manuel Schlageter; Luigi Maria Terracciano; Salvatore D'Angelo; Paolo Sorrentino
Journal:  World J Gastroenterol       Date:  2014-11-21       Impact factor: 5.742

4.  Comprehensive analysis of The Cancer Genome Atlas reveals a unique gene and non-coding RNA signature of fibrolamellar carcinoma.

Authors:  Timothy A Dinh; Eva C M Vitucci; Eliane Wauthier; Rondell P Graham; Wendy A Pitman; Tsunekazu Oikawa; Mengjie Chen; Grace O Silva; Kevin G Greene; Michael S Torbenson; Lola M Reid; Praveen Sethupathy
Journal:  Sci Rep       Date:  2017-03-17       Impact factor: 4.379

5.  Underexpression of miR-34a in hepatocellular carcinoma and its contribution towards enhancement of proliferating inhibitory effects of agents targeting c-MET.

Authors:  Yiwu Dang; Dianzhong Luo; Minhua Rong; Gang Chen
Journal:  PLoS One       Date:  2013-04-10       Impact factor: 3.240

6.  DNA repair gene XRCC1 Arg194Trp polymorphism and susceptibility to hepatocellular carcinoma: A meta-analysis.

Authors:  Wenyan Li; Feng Yang; Yongxian Gui; Junjie Bian
Journal:  Oncol Lett       Date:  2014-07-15       Impact factor: 2.967

7.  HEPATOCELLULAR CARCINOMA IN A NON-CIRRHOTIC PATIENT WITH SUSTAINED VIROLOGICAL RESPONSE AFTER HEPATITIS C TREATMENT.

Authors:  Angelo Alves de Mattos; Patrícia dos Santos Marcon; Fernanda Schild Branco de Araújo; Gabriela Perdomo Coral; Cristiane Valle Tovo
Journal:  Rev Inst Med Trop Sao Paulo       Date:  2015-12       Impact factor: 1.846

8.  Immunohistochemical Typing of Adenocarcinomas of the Pancreatobiliary System Improves Diagnosis and Prognostic Stratification.

Authors:  Carlos Fernández Moro; Alejandro Fernandez-Woodbridge; Melroy Alistair D'souza; Qianni Zhang; Benedek Bozoky; Senthil Vasan Kandaswamy; Piera Catalano; Rainer Heuchel; Sonia Shtembari; Marco Del Chiaro; Olof Danielsson; Mikael Björnstedt; J Matthias Löhr; Bengt Isaksson; Caroline Verbeke; Béla Bozóky
Journal:  PLoS One       Date:  2016-11-09       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.